Anavex Life Sciences Corp. has appointed Terrie Kellmeyer, Ph.D., as its permanent President and Chief Executive Officer and as a member of the Board of Directors, effective November 1, 2026. Dr. Kellmeyer, who had been serving as Interim CEO since May 2026, will maintain an annual base salary of $500,000 with an anticipated 30% bonus. The appointment follows her leadership during a period of clinical program focus and increased engagement with the FDA.
Three directors, including Board Chair Dr. Jiong Ma, resigned from the Board of Anavex Life Sciences Corp. effective October 28, 2026. The resignations of Dr. Ma, Mr. Gautam Patel, and Dr. Adrian Senderowicz were due to disagreements regarding the company's strategic direction and business plan execution. The company subsequently reconstituted its Audit, Compensation, and Nominating committees on November 1, 2026.